Digest Network Come funziona
Network
/
Società
Xy
Non verificato

XyloCor Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaCardiologiaFarmaceuticaMedicina - VarieSalute

4 comunicati stampa

Guarda tutti i comunicati
05/03/2026
Mercato del lavoro
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Cardiologia
XyloCor Appoints John Tucker as President and Chief Executive Officer
Fonte
XyloCor Therapeutics, Inc.
Emittente
Business Wire
1.00
0
10/07/2025
Medicina - Varie
Igiene alimentare
Biotecnologia
Cardiologia
Sanità
Farmaceutica
Salute
Oncologia
Industria
First Patient Dosed in XyloCor Therapeutics’ Phase 2b EXACT-2 Trial Evaluating XC001 for the Treatment of Coronary Artery Disease
Fonte
XyloCor Therapeutics, Inc.
Emittente
Business Wire
1.00
0
07/01/2025
Industria
Salute
Medicina - Varie
Biotecnologia
Farmaceutica
Cardiologia
XyloCor Therapeutics Raises $67.5 Million in Series B Financing to Advance Clinical Development of Novel Gene Therapy in Cardiovascular Disease
Fonte
XyloCor Therapeutics, Inc.
Emittente
Business Wire
1.00
0
10/07/2024
Mercato del lavoro
Attrezzature medico-sanitarie
Salute
Biotecnologia
Medicina - Varie
Cardiologia
XyloCor Therapeutics and SmartCella Enter into License Agreement for Use of the Extroducer Infusion Catheter System to Administer Novel Gene Therapy XC001 to the Heart
Fonte
XyloCor Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0